E
Egalet
Pharmaceutical company developing proprietary, abuse-deterrent products for the treatment of pain and in other indications
About Egalet
Assertio Holdings, Inc., trading under the ticker ASRT on the Nasdaq Global Select Market, is a commercial-stage pharmaceutical company based in Lake Forest, Illinois. The company specializes in developing and marketing treatments for pain and neurology disorders. Assertio operates in the pharmaceutical industry, targeting healthcare providers and patients who require effective pain management solutions. The company's business model revolves around the commercialization of its proprietary drug formulations and innovative drug delivery technologies. Assertio generates revenue through the sale of its pharmaceutical products, leveraging strategic partnerships and mergers to expand its market reach. Notably, the company completed a merger with Zyla Life Sciences and has strategically sold assets like the NUCYNTA franchise and Gralise, generating significant capital to repay debt and invest in future growth. Assertio's focus on cost synergies and strategic asset management positions it as a competitive player in the pharmaceutical market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1995
- Headquarters
- Værløse, Denmark
- Listing
- IPO 2019
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Performance Management, Biotechnology, Pay Per Result, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Mar 2019 | $0 | — | Undisclosed | — |
| POST IPO DEBTDebt | Sep 2016 | $40M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $81M | 0% |
| 2025 | $81M | 0% |
| 2024 | $81M | 0% |
| 2023 | $81M | 0% |
| 2022 | $81M | 0% |
| 2021 | $81M | 0% |
| 2020 | $81M | — |
Growth signals
Latest recorded traffic for Egalet is 310 monthly website visits, up 40.9% over the last three months. Egalet's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Index Ventures
Atlas Venture
Heartcore Capital
Omega Funds
Medicxi
Sunstone Life Science Ventures
Series B and later2 investors entered at this stage
BioFund Management
Danske Bank
Other known investors1 additional known investor
Hercules Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Egalet on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Egalet’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.